Title (R1400-ST-1113) Phase I Study of REGN1400 in Combination with Erlotinib or Cetuximab Administered in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) or Head and Neck Cancer (SCCHN)
Principal Investigator Alex Adjei, MD PhD
Study Number 219912
Summary The primary objective of the study is to characterize the safety profile of REGN1400 administered intravenously (IV) as monotherapy and in combination with erlotinib or cetuximab in patients with advanced NSCLC, CRC or SCCHN.
Eligibility Please see ClinicalTrials.gov link above.